Legal News In Brief
Executive Summary
Enzo and Illumina settle patent battle; Bard and Gore argue over jury logistics for an upcoming trial; and former employee alleges False Claims Act violations by medical equipment maker Lincare.
You may also be interested in...
High Court Gives Stryker Second Shot At Enhanced Damages
A Supreme Court verdict handed down June 13 would give manufacturers a better chance at winning enhanced damages in patent suits.
Bard set for Gore money soon as Q3 "solid"
CR Bard had a “solid” third quarter, beating analyst expectations across all divisions and seeing margin expansion, noted Jefferies’ Raj Denhoy. Standout performances came in its vascular and surgical divisions, which saw sales of $209.9m (+4% year-on-year) and $118.1m (+10% year-on-year), versus analyst estimates of $199m and $115m, respectively. The former was driven by its Lutonix drug-eluting balloon, while the latter was helped by the surgical sealant contribution from Neomend, which Bard acquired last year (www.clinica.co.uk, 24 October 2012).
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.